NIH, Partners To Launch Phase 3 Trial To Evaluate HIV Vaccine Efficacy In MSM, Transgender People

National Institutes of Health: NIH and partners to launch HIV vaccine efficacy trial in the Americas and Europe
“The National Institutes of Health and partners [Monday] announced plans to conduct a Phase 3 HIV vaccine efficacy trial at multiple clinical research sites in North America, South America, and Europe. The trial, called HPX3002/HVTN 706 or Mosaico, will assess whether an investigational vaccine regimen designed to induce immune responses against a variety of global HIV strains can safely and effectively prevent HIV acquisition among men who have sex with men and transgender people…” (7/15).